Pages that link to "Q27725163"
Jump to navigation
Jump to search
The following pages link to Journal for Immunotherapy of Cancer (Q27725163):
Displaying 50 items.
- Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model (Q22001064) (← links)
- A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer (Q22001066) (← links)
- B cell regulation of the anti-tumor response and role in carcinogenesis (Q26738867) (← links)
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? (Q26741101) (← links)
- Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine (Q26748727) (← links)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (Q26765115) (← links)
- From bench to bedside a comprehensive review of pancreatic cancer immunotherapy (Q26765123) (← links)
- Metabolic communication in tumors: a new layer of immunoregulation for immune evasion (Q26765256) (← links)
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy (Q26770780) (← links)
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer (Q26775471) (← links)
- Pembrolizumab (Q26796435) (← links)
- Primer on tumor immunology and cancer immunotherapy (Q27001126) (← links)
- Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation (Q27027876) (← links)
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations (Q28066738) (← links)
- Clinical significance of tumor-infiltrating lymphocytes in breast cancer (Q28070214) (← links)
- Adjuvants for peptide-based cancer vaccines (Q28072236) (← links)
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation (Q28075719) (← links)
- Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study (Q28084489) (← links)
- A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial (Q28088679) (← links)
- Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor (Q28468290) (← links)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (Q28553703) (← links)
- Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer (Q29248716) (← links)
- Canine cancer immunotherapy studies: linking mouse and human (Q30239893) (← links)
- Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature (Q30275135) (← links)
- Current clinical trials testing the combination of immunotherapy with radiotherapy. (Q30356447) (← links)
- A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes (Q30411269) (← links)
- Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma (Q30412300) (← links)
- Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells (Q30591778) (← links)
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma (Q30641952) (← links)
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program (Q33415481) (← links)
- Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy (Q33439649) (← links)
- Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors (Q33572938) (← links)
- Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy (Q33572965) (← links)
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies (Q33572971) (← links)
- Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer (Q33576409) (← links)
- A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma (Q33606083) (← links)
- Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts (Q33606096) (← links)
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study (Q33606102) (← links)
- Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer (Q33606107) (← links)
- Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy (Q33606111) (← links)
- Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response (Q33606132) (← links)
- Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma (Q33606137) (← links)
- Rational combinations of immunotherapeutics that target discrete pathways (Q33606144) (← links)
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment (Q33606150) (← links)
- Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells (Q33606156) (← links)
- Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors (Q33606161) (← links)
- Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses (Q33606166) (← links)
- Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer (Q33689478) (← links)
- Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. (Q33691858) (← links)
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines (Q33692070) (← links)